NCT07544654 2026-04-22
A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
Boehringer Ingelheim
Moonlight Bio, Inc
AccSalus Biosciences, Inc.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Hansoh BioMedical R&D Company
Power Life Sciences Inc.
Power Life Sciences Inc.